期刊文献+

亚健康中医药干预效果评价体系的构建思路 被引量:11

Construction of effectiveness evaluation system for traditional Chinese medicine interventions in subhealth
下载PDF
导出
摘要 亚健康对人们生活质量的影响及其高发生率,使得对亚健康状态有效干预措施的需求日益突显,同时,如何评价中医药对亚健康的干预效果也成为值得探索的问题。亚健康的概念宽泛,包括多种不同的类型,如躯体性亚健康和心理性亚健康等;或者以某一种不适症状表现为主,如疲劳性亚健康和疼痛性亚健康等。亚健康人群表现复杂多样,缺乏明确的实验室判定指标;一些主要症状容易受到情境的影响而产生波动。这些因素增加了亚健康干预效果评价的难度。以典型的亚健康状态类型作为研究的切入点,在针对常见中医证候类型而设立的中医药干预方案的基础上,以受试者最关注的中间结局指标为选择原则,确定主、次指标,选择多时点评价的多维度、多层次指标评价体系,是较为客观、可行的亚健康中医药干预效果评价的模式。 The demand of effective interventions in subhealth is growing with more and more people being in subhealth state and poor life quality. It is important to explore how to evaluate the effects of the traditional Chinese medicine (TCM) interventions in subhealth, but it is difficult to conduct such an evaluation because of the broad meaning and varied types of subhealth, such as physical or psychological subtypes. The subtypes may be characterized by one of the symptoms like fatigue or pain, etc. Many symptoms of subhealth have no clear laboratory markers for diagnosis, and some symptoms may fluctuate with psychological and environmental factors. All of the above factors would increase the difficulty of effectiveness evaluation. The typical subtype of subhealth state and the intermediate outcome should be chosen for multidimensionally evaluating the effects of TCM interventions in subhealth at different time points.
出处 《中西医结合学报》 CAS 2009年第3期201-204,共4页 Journal of Chinese Integrative Medicine
基金 "十一五"国家科技支撑计划重点项目(No.2006BAI13B05) 国家基础科学人才培养基金科研训练项目
关键词 亚健康 中医学 干预性研究 治疗效果 subhealth traditional Chinese medicine intervention studies treatment outcome
  • 相关文献

参考文献9

二级参考文献29

  • 1刘保延,何丽云,谢雁鸣,胡镜清.亚健康状态中医基本证候特征调查问卷的研制[J].中国中医基础医学杂志,2004,10(9):23-28. 被引量:111
  • 2林桂珍,钟兰英.亚健康的发生因素及其治疗[J].中药研究与信息,2004,6(10):26-28. 被引量:18
  • 3于春泉,张伯礼,马寰.亚健康状态主要类型及流行病学调查现状[J].天津中医学院学报,2005,24(2):91-93. 被引量:39
  • 4Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA.1999 ;282(8): 786-790.
  • 5Johnston K. What are surrogate outcome measures and why do they fail in clinical research? Neuroepidemiology 1999; 18(4): 167-173.
  • 6The Cochrance Reviewer' Handbook Glossary (Version 4.1.4), 26-27. The Cochrane Collaboration 2001.
  • 7Chuang-Stein C, DeMasi R. Surrogate endpoints in AIDS drug development: current status. Drug Information J 1998;32: 439-448, 457-459.
  • 8Gould AL. Discussion of "Surrogate endpoints in AIDS drug evelopment: current status" by C. Chuang-Stein and Ralph DeMasi. Drug Information J 1998 ;32: 453-456.
  • 9Hill AM, DeMasi R, Dawson D. Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death. Antivir Ther 1998 ;3(3) :139-145.
  • 10Ellenberg SS. Commentary on "Surrogate endpoints in AIDS drug development: current status"by C. chuang-stein and R.DeMasi. Drug Information J 1998;32:453-456.

共引文献547

同被引文献129

引证文献11

二级引证文献141

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部